Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ
29.65
+0.15 (+0.51%)
Real-time Data
01:30 PM
Day's Range
29.1529.77
52 wk Range
19.6930.96
Financial Statements - ACAD - Acadia Pharmaceuticals Inc.
Revenue
1.07B▲ 11.9%
Net Income
391.00M▲ 72.7%Net Margin 36.5%
EBITDA
116.57M▲ 351.5%
Free Cash Flow
105.14M▼ 33.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 1.07B | 957.79M | 726.43M | 517.23M | 484.14M | 441.75M |
| Cost of Goods | 88.99M | 81.84M | 41.63M | 10.16M | 19.14M | 20.55M |
| Gross Profit | 982.50M | 875.95M | 684.79M | 507.06M | 465M | 421.20M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 104.81M | 84.27M | -73.37M | -223.59M | -170.43M | -286.58M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 2.37M | 148.33M | 5.10M | 3.54M | 2.32M | -997K |
| Pre Tax Income | 138.90M | 258.07M | -51.03M | -213.44M | -167.51M | -280.97M |
| Income Tax | -252.09M | 31.62M | 10.25M | 2.53M | 351K | 611K |
| Net Income | 391M | 226.45M | -61.28M | -215.97M | -167.87M | -281.58M |
| EPS Basic | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 | -1.79 |
| EPS Diluted | 2.3 | 1.36 | -0.37 | -1.34 | -1.05 | -1.79 |
| Basic Shares Outstanding | 168.35M | 165.71M | 163.81M | 161.68M | 160.49M | 157.33M |
| Diluted Shares Outstanding | 168.35M | 165.71M | 163.81M | 161.68M | 160.49M | 157.33M |
| Ebit | 104.81M | 84.27M | -73.37M | -223.59M | -170.43M | -286.58M |
| Ebitda | 116.57M | -46.35M | -67.82M | -221.57M | -167.09M | -283.65M |
| Net Income Continuous Operations | 391M | 226.45M | -61.28M | -215.97M | -167.87M | -281.58M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
